Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Meenakshi AnuragEric J JaehnigKarsten KrugJonathan T LeiErik J BergstromBeom-Jun KimTanmayi D VashistAnh Minh Tran HuynhYongchao DouXuxu GouChen HuangZhiao ShiBo WenViktoriya KorchinaRichard A GibbsDonna M MuznyHarsha Vardhan DoddapaneniLacey Elizabeth DobroleckiHenry RodriguezAna I RoblesTara HiltkeMichael T LewisJulie R NangiaMaryam Nemati ShafaeeShunqiang LiIan S HagemannJeremy HoogBora LimC Kent OsborneD R ManiMichael A GilletteBing ZhangGloria V EcheverriaGeorge MilesMothaffar F RimawiSteven A CarrFoluso O AdemuyiwaShankha SatpathyMatthew J EllisPublished in: Cancer discovery (2022)
Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of chemotherapy response associations, including a 19q13.31-33 somatic deletion encoding genes serving lagging-strand DNA synthesis (LIG1, POLD1, and XRCC1), that correlate with lack of pathologic response, carboplatin-selective resistance, and, in pan-cancer studies, poor prognosis and CIN. This article is highlighted in the In This Issue feature, p. 2483.